Physician profile
Emilio Blanco
NPI 1902987688
$2,696.81
in general payments reported to CMS, 2019-2025
35 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $298 · 2021: $644 · 2022: $654 · 2023: $311 · 2024: $159 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.08 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.30 | 2019-2023 | Lo Loestrin Fe |
| Gynesonics, INC. | $293.36 | 2021-2022 | |
| Coopersurgical, INC. | $181.62 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $174.90 | 2019-2023 | |
| Therapeuticsmd, INC. | $162.61 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $119.49 | 2021-2025 | |
| Mylan Pharmaceuticals INC. | $114.66 | 2019-2022 | |
| Smith+Nephew, INC. | $99.79 | 2022-2025 | Pico 14 |
| Organon LLC | $94.31 | 2022 | |
| Myovant Sciences INC. | $88.03 | 2021-2022 | |
| Hologic Sales and Service, LLC | $84.53 | 2020-2023 | Aptima, Affirm Prone Biopsy System |
| Exeltis, USA INC. | $78.79 | 2020-2025 | Slynd |
| Scynexis, INC. | $74.28 | 2022 | |
| Astellas Pharma US INC | $71.91 | 2025 | Veozah |
| Lupin INC. | $69.15 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $67.74 | 2023-2024 | Myfembree |
| Agile Therapeutics, INC. | $60.46 | 2021-2023 | Twirla |
| Millicent US INC | $57.17 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Mission Pharmacal Company | $56.08 | 2021-2024 | Ferralet 90 |
| Daiichi Sankyo INC. | $32.51 | 2019 | |
| Dexcom, INC. | $24.89 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $24.04 | 2024 | |
| Roche Diagnostics Corporation | $22.61 | 2021 | |
| Solventum Corporation | $21.62 | 2025 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Baxter Healthcare | $19.30 | 2025 | Perclot |
| Shield Therapeutics INC | $17.90 | 2022 | |
| Evofem Biosciences, INC. | $17.78 | 2025 | Solosec, Phexx, Phexxi |
| Biogen, INC. | $17.58 | 2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $16.54 | 2019 | |
| Zyla Life Sciences, INC. | $14.89 | 2020 | |
| Innovation Technologies INC | $13.55 | 2025 | Irrisept |
| Amag Pharmaceuticals, INC. | $13.20 | 2019 | |
| Avion Pharmaceuticals | $12.94 | 2022 | |
| Covidien LP | $11.28 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilio Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.